Verzenio Archives -

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

https://pharmaphorum.com/news/lillys-verzenios-gets-nice-blessing-for-early-stage-breast-cancer/

After rejecting Eli Lilly’s Verzenios for breast cancer therapy earlier this year, NICE has relented, recommending the drug

NICE changes stance on Lilly’s breast cancer dug Verzenios

https://pharmaphorum.com/news/nice-changes-stance-on-lillys-breast-cancer-dug-verzenio/

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set

Ibrance trial failure dashes Pfizer’s growth hopes for the drug

https://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/

Lilly’s Verzenio has failed to show benefits in lung cancer patients with a KRAS mutation, denting the company’s

Lilly’s Verzenio fails in KRAS-mutated lung cancer

https://pharmaphorum.com/news/verzenio-fails-lung-cancer/

Verzenio